Ad
Friday, 25 May 2018
AstraZeneca cancer drug hits second goal by extending survival
LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment